Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PediDOSE: Age-based midazolam for pediatric seizures
NCT05121324Phase 3Recruiting
- Sponsor
- Stanford University
- Start
- Aug 2022
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of midazolam in epilepsy (2 arms), sponsored by Stanford University. Primary endpoint: Seizing on emergency department arrival at 10 months. Started Aug 2022; status: recruiting.
02
Drugs
midazolam
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT05121324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05121324.